Latest in Cardiology from ACC.org

• CKD Studies Spotlight GFR Measurement, Finerenone Benefit and Rivaroxaban Risk
  Research presented at the European Renal Association Congress, held June 3-6 in Glasgow, Scotland, highlighted new findings in chronic kidney disease (CKD), including evidence supporting more precise GFR assessment and trial results on finerenone in nondiabetic CKD and rivaroxaban in advanced CKD patients with CV risk factors.
• Follow-Up of FAVOR III Suggests QFR-Guided PCI Improves 5-Year Outcomes
  When compared with angiography guidance, quantitative flow ratio (QFR)-guided PCI improved five-year clinical outcomes with benefits primarily achieved in the first two years, according to a follow-up study of the multicenter, sham-controlled FAVOR III trial published June 10 in JACC.
• Follow-Up of CENTRAL, DIRECT-PLUS Suggests Visceral Fat Reduction Has Lasting Metabolic Health Benefits
  A long-term follow-up of the CENTRAL and DIRECT-PLUS trials published in Circulation suggests that despite long-term weight regain, visceral fat reduction during lifestyle intervention is associated with sustained improvements in metabolic health.
• SOGALDI-PEF: Baseline Renin Levels Predict BP Treatment Effect
  Patients with low plasma renin levels had a more pronounced blood pressure (BP) reduction with spironolactone/dapagliflozin vs. dapagliflozin alone, in addition to seeing a more favorable impact on cardiovascular structure and function, while aldosterone levels exhibited no predictive value in treatment response...
• Eagle’s Eye View: Impact of Semaglutide And Survival Outcomes In Patients With T2D and CKD
  In this week’s View, Dr. Eagle highlights several noteworthy developments shaping cardiovascular and renal care.